High Expression Levels of miR-21 and miR-210 Predict Unfavorable Survival in Breast Cancer: A Systemic Review and Meta-Analysis

2015 ◽  
Vol 30 (4) ◽  
pp. 347-358 ◽  
Author(s):  
Yiting Tang ◽  
Xifa Zhou ◽  
Jianfeng Ji ◽  
Ling Chen ◽  
Jianping Cao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Negative Impact ◽  
Meta Analysis ◽  
Survival Rates ◽  
Prognostic Biomarkers ◽  
High Expression ◽  
Systemic Review ◽  
Breast Cancer Patients ◽  
Expression Levels

Background MicroRNAs (miRNAs) have been emerging as valuable prognostic biomarkers of breast cancer. We therefore summarized recent research into miRNAs involved in human breast cancer and, further, completed a meta-analysis to predict the role of specific miRNAs in the survival of breast cancer patients. Methods Studies were identified by searching PubMed, Embase and Web of Science. Descriptive characteristics for studies were described, and an additional meta-analysis for specific miRNAs was performed. Pooled hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) were calculated. Results A total of 41 articles including 27 types of miRNAs were found regarding prognostic biomarkers for breast cancer survival, of which, micRNA-21 (miR-21) was the most-studied specific miRNA that appeared repeatedly among the selected classifiers. For the studies evaluating miR-21's association with clinical outcomes, the median HR in the studies was 2.32 (interquartile range [IQR] = 1.04-3.40), and the pooled HR suggested that high expression of miR-21 has a negative impact on overall survival (OS; HR = 1.46, 95% CI, 1.25-1.70; p<0.05) and disease/recurrence-free survival in breast cancer (HR = 1.49, 95% CI, 1.17-1.90; p<0.01). We also found that higher expression levels of miR-210 significantly predicted poorer outcome, with median HR in the reported studies of 4.07 (IQR = 1.54-4.43) and a pooled HR of 2.94 (95% CI, 2.08-4.17; p<0.05). Conclusions These results indicate that miRNAs show promising associations with prognosis in breast cancer. Moreover, specific miRNAs such as miR-21 and miR-210 can predict poor survival rates in breast cancer patients.

Solamargine induces apoptosis and enhances susceptibility to trastuzumab and epirubicin in breast cancer cells with low or high expression levels of HER2/neu

2008 ◽  
Vol 29 (1) ◽  
pp. 35-45 ◽  
Author(s):  
Li Yen Shiu ◽  
Chia Hua Liang ◽  
Li Ching Chang ◽  
Hamm Ming Sheu ◽  
Eing Mei Tsai ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Cancer Patients ◽  
Breast Cancer Cells ◽  
Topoisomerase Ii ◽  
Growth Factor Receptor ◽  
High Expression ◽  
Breast Cancer Patients ◽  
Expression Levels ◽  
Topoisomerase Ii Α

Trastuzumab is used for breast cancer patients with high expression levels of HER2 (human epidermal growth factor receptor 2)/neu; however, it has no effect on cancers with low levels of HER2/neu. SM (solamargine), a major steroidal alkaloid glycoside purified from Solanum incanum, triggered apoptosis of breast cancer cells (MCF-7 and SK-BR-3 cells) and non-cancerous breast epithelial cells (HBL-100 cells) within 3 h. To extend the application of trastuzumab in breast cancer patients, the regulation of HER2/neu expression by SM was investigated. SM significantly up-regulates HER2/neu expression in breast cancer cells with low and high expression levels of HER2/neu, and synergistically enhanced the effect of trastuzumab in inhibiting cell proliferation. Additionally, HER2/neu and TOP2A [TopoII (topoisomerase II) α] genes share the same amplicon on an identical chromosome. Notably, SM co-regulates HER2/neu and TopoIIα expression markedly, and enhances TopoII inhibitor–EPI (epirubicin)-induced cytotoxicity to breast cancer cells.

scholarly journals Circulating LncRNAs Landscape as Potential Biomarkers in Breast Cancer

2021 ◽  
Author(s):  
Zahra Pourramezan ◽  
Fatemeh Akhavan Attar ◽  
Maryam Yusefpour ◽  
Masoumeh Azizi ◽  
Mana Oloomi
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Tumor Size ◽  
Survival Rates ◽  
Therapeutic Targets ◽  
Female Breast Cancer ◽  
Breast Cancer Patients ◽  
Blood Samples ◽  
Expression Levels ◽  
Delay In Diagnosis

Abstract The delay in diagnosis and treatment of breast cancer results in low survival rates and high mortality. Thus, it is essential to characterize new therapeutic targets and prognostic breast cancer biomarkers. The rising evidence suggested that long non-coding RNAs (lncRNAs) expression levels are deregulated in human cancers and can use as biomarkers for the rapid diagnosis of breast cancer. In the present study, a Quantitative Real-time polymerase chain reaction (qRT-PCR) technique was used to measure twenty oncogenic and tumor suppressor lncRNAs expression levels in whole blood samples of breast cancer patients and normal controls. Blood samples from 30 healthy women and 30 female breast cancer patients were collected. Then cDNA was synthesized from the extracted RNA blood. The expression level of lncRNAs measured and analyzed by LinReg PCR and REST software and the correla­tion between lncRNAs dysregulation and clinical characteristics and prognosis were also analyzed by SPSS software. The comparison between the expression levels of lncRNAs in the blood samples of breast cancer patients compared with healthy individuals revealed that some lncRNAs (MEG3, NBAT1, NKILA, GAS5, EPB41L4A-AS2, ZFAS1, MVIH, Z38, and BC040587) were down regulated. In contrast, other lncRNAs (H19, SPRY4-IT1, UCA1, AC026904.1, CCAT1) were up-regulated, significantly. It was shown that the expression levels of NKILA, NBAT1, and ZFAS1 lncRNAs were related to tumor size, and BC040587expression level related to age, node metastasis, tumor size, and grade (P<0.05). The association between H19 and SPRY4-IT1 lncRNAs with HER-2 was confirmed statistically (P<0.05). Our data highlighted the correlation of BC040587, H19, and SPRY4-IT1 lncRNAs with clinicopathological traits in breast cancer patients suggesting their future applications as novel biomarkers and therapeutic targets in breast cancer. In conclusion, circulating lncRNAs could consider as the prognostic and predictive markers in breast cancer.

scholarly journals Serum Long Non-Coding RNAs PVT1, HOTAIR, and NEAT1 as Potential Biomarkers in Egyptian Women with Breast Cancer

Biomolecules ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 301
Author(s):  
Amal Ahmed Abd El-Fattah ◽  
Nermin Abdel Hamid Sadik ◽  
Olfat Gamil Shaker ◽  
Amal Mohamed Kamal ◽  
Nancy Nabil Shahin
Keyword(s):  
Breast Cancer ◽  
Logistic Regression ◽  
Cancer Patients ◽  
Breast Cancer Diagnosis ◽  
Serum Levels ◽  
Breast Cancer Patients ◽  
Multivariate Logistic Regression ◽  
Expression Levels ◽  
Non Coding Rnas ◽  
Pai 1

Long non-coding RNAs play an important role in tumor growth, angiogenesis, and metastasis in several types of cancer. However, the clinical significance of using lncRNAs as biomarkers for breast cancer diagnosis and prognosis is still poorly investigated. In this study, we analyzed the serum expression levels of lncRNAs PVT1, HOTAIR, NEAT1, and MALAT1, and their associated proteins, PAI-1, and OPN, in breast cancer patients compared to fibroadenoma patients and healthy subjects. Using quantitative real-time PCR (qRT-PCR), we compared the serum expression levels of the four circulating lncRNAs in patients with breast cancer (n = 50), fibroadenoma (n = 25), and healthy controls (n = 25). The serum levels of PAI-1 and OPN were measured using ELISA. Receiveroperating-characteristic (ROC) analysis and multivariate logistic regression were used to evaluate the diagnostic value of the selected parameters. The serum levels of HOTAIR, PAI-1, and OPN were significantly higher in breast cancer patients compared to controls and fibroadenoma patients. The serum level of PVT1 was significantly higher in breast cancer patients than in the controls, while that of NEAT1 was significantly lower in breast cancer patients compared to controls and fibroadenoma patients. Both ROC and multivariate logistic regression analyses revealed that PAI-1 has the greatest power in discriminating breast cancer from the control, whereas HOTAIR, PAI-1, and OPN have the greatest power in discriminating breast cancer from fibroadenoma patients. In conclusion, our data suggest that the serum levels of PVT1, HOTAIR, NEAT1, PAI-1, and OPN could serve as promising diagnostic biomarkers for breast cancer.

scholarly journals Do early HER2-overexpression breast cancer patients benefit from undergoing neoadjuvant trastuzumab and mastectomy? A meta-analysis

2019 ◽  
Vol Volume 11 ◽  
pp. 8043-8054 ◽  
Author(s):  
Lin He ◽  
Qian Wu ◽  
Jing Xiong ◽  
Zhumin Su ◽  
Biyuan Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Her2 Overexpression ◽  
Breast Cancer Patients

scholarly journals Comparison of the clinical effectiveness of treatments for aromatase inhibitor-induced arthralgia in breast cancer patients: a protocol for a systematic review and network meta-analysis

BMJ Open ◽  
2020 ◽  
Vol 10 (5) ◽  
pp. e033461
Author(s):  
Kyeore Bae ◽  
Si Yeon Song
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Pain Intensity ◽  
Aromatase Inhibitor ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Indirect Evidence ◽  
Secondary Outcome ◽  
Breast Cancer Patients ◽  
Patient Reported

IntroductionAromatase inhibitor-induced arthralgia (AIA) is a major adverse event of aromatase inhibitors (AIs) and leads to premature discontinuation of AI therapy in breast cancer patients. The objective of this protocol for a systematic review and network meta-analysis (NMA) is to provide the methodology to compare the change in pain intensity between different AIA treatments and demonstrate the rank probabilities for different treatments by combining all available direct and indirect evidence.Methods and analysisPubMed, the Cochrane Controlled Register of Trials (CENTRAL), EMBASE, Web of Science and ClinicalTrials.gov will be searched to identify publications in English from inception to November 2019. We will include randomised controlled trials (RCTs) assessing the effects of different treatments for AIA in postmenopausal women with stage 0–III hormone receptor-positive breast cancer. The primary endpoints will be the change in patient-reported pain intensity from baseline to post-treatment. The number of adverse events will be presented as a secondary outcome.Both pairwise meta-analysis and NMA with the Frequentist approach will be conducted. We will demonstrate summary estimates with forest plots in meta-analysis and direct and mixed evidence with a ranking of the treatments as the P-score in NMA. The revised Cochrane risk-of-bias tool for randomised trials will be used to assess the methodological quality within individual RCTs. The quality of evidence will be assessed.Ethics and disseminationAs this review does not involve individual patients, ethical approval is not required. The results of this systematic review and NMA will be published in a peer-reviewed journal. This review will provide valuable information on AIA therapeutic options for clinicians, health practitioners and breast cancer survivors.PROSPERO registration numberCRD42019136967.

Sign in / Sign up

Export Citation Format

Share Document